# PLB-005

Source: https://onco.cc/drugs/plb-005/  
OnCo record `plb-005` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PLB-005 is an experimental dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics, in preclinical development for solid tumours.

## Summary

PLB-005 is a dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics. Dual-payload antibody-drug conjugate in PrimeLink's pipeline; the target is not disclosed in the sources read. Its furthest stage is preclinical development, for solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Listed on the pipeline page (columns: discovery, preclinical, IND, phase I); the stage bar is graphical and was not read; no registry entry found for this code via the v2 API. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: PLB-005
- Modality: Dual-payload antibody-drug conjugate
- Mechanism: Dual-payload antibody-drug conjugate in PrimeLink's pipeline; the target is not disclosed in the sources read.

## Sources

- PrimeLink BioTherapeutics: primelinkbio.com: https://www.primelinkbio.com/pipeline/1.html

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [PrimeLink BioTherapeutics](https://onco.cc/companies/primelink-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/plb-005.json